Schrier Robert W, Bansal Shweta
Division of Renal Disease and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado, USA.
Curr Opin Crit Care. 2008 Dec;14(6):627-34. doi: 10.1097/MCC.0b013e32830e45e3.
Hyponatremia is the most common electrolyte disorder present in hospitalized patients. Acute and severe hyponatremia can cause significant morbidity and mortality. The present review discusses the epidemiology, causes, and a practical approach to the diagnosis and management of acute and chronic hyponatremia, including the appropriate use of hypertonic saline and potential future use of the new V2 vasopressin receptor antagonists in critically ill patients.
The increasing knowledge of aquaporin water channels and the role of vasopressin in water homeostasis have enhanced our understanding of hyponatremic disorders. Increased vasopressin secretion due to nonosmotic stimuli leads to decreased electrolyte-free water excretion with resulting water retention and hyponatremia. Vasopressin receptor antagonists induce electrolyte-free water diuresis without natriuresis and kaliuresis. Phase three trials indicate that these agents predictably reduce urine osmolality, increase electrolyte-free water excretion, and raise serum sodium concentration. They are likely to become a mainstay of treatment of euvolemic and hypervolemic hyponatremia.
The correct diagnosis and management of hyponatremia is complex and requires a systematic approach. Vasopressin receptor antagonists are potential tools in the management of hyponatremia. Further studies are needed to determine their role in the treatment of acute, severe, life-threatening hyponatremia as well as chronic hyponatremia.
低钠血症是住院患者中最常见的电解质紊乱。急性重度低钠血症可导致显著的发病率和死亡率。本综述讨论了急性和慢性低钠血症的流行病学、病因以及诊断和管理的实用方法,包括高渗盐水的合理使用以及危重症患者未来可能使用新型V2血管加压素受体拮抗剂。
对水通道蛋白水通道以及血管加压素在水稳态中的作用的认识不断增加,增强了我们对低钠血症疾病的理解。非渗透性刺激导致血管加压素分泌增加,导致无电解质水排泄减少,从而导致水潴留和低钠血症。血管加压素受体拮抗剂可诱导无电解质水利尿,而不伴有钠利尿和钾利尿。三期试验表明,这些药物可预测地降低尿渗透压,增加无电解质水排泄,并提高血清钠浓度。它们可能会成为等容性和高容性低钠血症治疗的主要手段。
低钠血症的正确诊断和管理很复杂,需要系统的方法。血管加压素受体拮抗剂是管理低钠血症的潜在工具。需要进一步研究以确定它们在治疗急性、重度、危及生命的低钠血症以及慢性低钠血症中的作用。